ITH is a biotech company located at the Karolinska Institutet and Karolinska University Hospital, dedicated to innovating the next generation of personalized therapeutics and diagnostics for patients with immune related diseases.
The company's research & development is focused on its award-winning Tailored Leukapheresis (TLA) immunotherapy for Immune Mediated Inflammatory Diseases - which has been developed with the support of the European Union, Swedish Research Council, and Swedish Governmental Agency for Innovation Systems.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ithgroup.eu
Immune Therapy Holdings Questions
Immune Therapy Holdings's website is ithgroup.eu
Immune Therapy Holdings's LinkedIn profile is https://se.linkedin.com/company/immune-therapy-holdings
Immune Therapy Holdings has
3 employees.
View email and phone details for 3
employees at Immune Therapy Holdings.
Immune Therapy Holdings's industry is
Biotechnology Research
Immune Therapy Holdings's top competitors are
Affibody Ab,
Pt. Meditech Manufaktur Indonesia,
Gesynta Pharma Ab,
Geras Solutions | Minnesmottagningen.se,
Invox,
Rfb Orient,
Neogap Therapeutics Ab,
Diamyd Medical,
Abc Labs,
Transmedic Group.
Immune Therapy Holdings's categories are Biotechnology Research
Immune Therapy Holdings's founding year is 2005
